Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5936778 | 0.95 | MEN1 (0.50) | MEN1NPC1KMT2AALDH1A1LMNA | |
| SCHEMBL2826140 | 0.91 | MEN1 (0.49) | MEN1NPC1KMT2AALDH1A1LMNA | |
| Water SCHEMBL5017516 | 0.90 | MEN1 (0.47) | MEN1NPC1KMT2AALDH1A1LMNA | |
| SCHEMBL3426953 | 0.87 | KMT2A (0.44) | MEN1NPC1KMT2AALDH1A1LMNA | |
| SCHEMBL9835426 | 0.86 | ALDH1A1 (0.44) | MEN1NPC1KMT2AALDH1A1LMNA | |
| SCHEMBL2694051 | 0.84 | ALDH1A1 (0.42) | MEN1NPC1KMT2AALDH1A1LMNA | |
| SCHEMBL135909 | 0.83 | HDAC1 (0.43) | MEN1NPC1KMT2AALDH1A1LMNA | |
| SCHEMBL20027757 | 0.83 | ALOX15 (0.44) | MEN1NPC1KMT2AALDH1A1LMNA | |
| Succinic Acid Diethyl Ester SCHEMBL27962258 | 0.82 | CYP1A2 (0.41) | MEN1NPC1KMT2AALDH1A1LMNA | |
| SCHEMBL4319039 | 0.81 | KMT2A (0.40) | MEN1NPC1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528124-B2 | 1,3-dihydro-2H-indol-2-one derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20060276449-A1 | 1,3-Dihydro-2h-indol-2-one derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1659121-A1 | 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-5652363-A | TREATING PLATELET ACTIVATING FACTOR MEDIATED DISEASES | C.D. SEARLE & CO. (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0670838-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO 4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5359073-A | Substituted-phenyl (N,N'-cycloalkyl/alkyl carboxamide)-1H/3H-imidazo[4,5-b]pyridine compounds as PAF antagonists | G. D. SEARLE & CO. (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994012500-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO[4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5302601-A | Useful in the treatment of diseases mediated by platelet activating factor | G. D. SEARLE & CO. (US) | 1994-04-12 | — | — | US | disclosed |
| US-5208242-A | 5-substituted-4-phenyl-5H-imidazo[4,5-c]pyridine derivatives | G. D. SEARLE & CO. (US) | 1993-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276449-A1 | 1,3-Dihydro-2h-indol-2-one derivative | AVPR1B, AVPR2, AVPR1A | MEN1 353/4885NPC1 2956/4885KMT2A 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.